STOUGHTON, Mass. , July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021 , at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a

STOUGHTON, Mass. , June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications

STOUGHTON, Mass. , May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference: Jefferies

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta ® Franchise and Adjusted EBITDA 2021 Guidance Range Raised   – – Colleen Tupper Appointed as Next CFO;  Paul Brannelly will be Leaving the Company to Pursue Other Opportunities   – –

STOUGHTON, Mass. , April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a

– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance   – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Collegium

STOUGHTON, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass. , Jan.